Pharmacist Considerations for Investigational Drug Studies

Seth Larkin, PharmD – University of Kentucky Investigational Drug Service Coordinator




I have no actual or potential conflicts of interest to disclose.

Learning Objectives

- Describe the roles and responsibilities of an investigational research pharmacist
- Discuss proper handling of investigational medications
- Recognize the importance of site-specific Standard Operating Procedures (SOPs) regarding investigational medications
- Identify common pharmacy related protocol deviations

Why Do We Have Investigational Research Pharmacists?

- Oversee proper handling, storage, and blinding of investigational drugs
- Source of knowledge for study drugs (Phases 1, 2 and 3)
- Provide added support to research team including:
 - Randomization
 - Drug accountability and disposition
 - Blinding/Unblinding



Compliance

- Ensure compliance with all federal (FDA, NIH, NCI), state, The Joint Commission, and IRB regulations concerning investigational medications
- Ensure compliance with all site-specific administrative, nursing, and pharmacy policies
- Implementation of research medication-specific policies compliant with USP 795 and 797, as well as creation of policies pertaining to USP 800 guidelines regarding research-specific medications












NIH = National Institutes of Health, NCI = National Cancer Institute, IRB = Institutional Review Board, USP = United States Pharmacopeia

Research and Development Activities

- Initial protocol review
- Assess the pharmacy's ability to accommodate the protocol
- Site qualification, initiation, and monitor visits
- Act as unblinded personnel (will break blind if necessary)
- Randomization
- Preparation of dosage forms
- Quality control





Basic IDS Activities

- Order investigational product (IP)
- Maintain inventory
- Process returns
- Assure appropriate storage of IP
- Prepare and package IP
- Compound, deliver, and dispense IP
- Provision of drug information
- Maintain proper medication records




National	Institutes of F Cancer Instit	ute		Division of Ca Cancer Thera	ncer Treatme py Evaluation	nt an Prog	d Diagnosis Iram		PAGE NO. CONTROL RECORD			
Invest	igational A	gent Accou	untability Record		SATELLITE RECORD							
Name of	f Institution:				NCI Protocol No.:							
Agent N	ame:				Dose Form and Strength:							
Protocol	Title:					Dispensing Area:						
Investig	ator Name:				CTEP Investigator ID:							
Line No.	Date	Patient's Initials	Patient's ID No.	Dose	Dispensed or		Balance Forward		Manufacturer and Lot No.	Recorder's		
					Received	Received Ba						
1.			-									
2.												
3.					-							
4.												
5.			-									
5.												
7												
В.			-									
9.												
10.		-										
11.										L		

Designated Staff and Locations

- Specific access for staff that receive and dispense investigational supply
- Investigational drug supply should be separated from commercial supply





FDA Requirements for Investigational Drug Storage

- FDA Code of Federal Regulations Title 21 Part 312
- Secure location with limited access
- Storage conditions comply with study protocol or instructions on the label of the drug
- Responsibilities of the Investigator:
 - Administer drug only to subjects under personal supervision of primary investigator (PI) or sub-investigator
 - Access to the drug is limited and not supplied to those not authorized to receive it







KENTUCKY HEMATOLOGY/ONCOLOGY PHARMACY SYMPOSIUM 2020



Investigational drugs that are FDA approved can be stored next to the same commercially available drug in order to save space.

FALSE

Investigational drug supply should be separated from commercial supply.

Standard Operating Procedures (SOPs)

- Implementation of investigational drug-specific SOPs
 - Receipt, inventory, safe handling and compounding, storage and security, transport and transfer of inventory, protocol review and training, return and disposal, and monitor/auditor visits.
- Transparency with sponsors/investigators
- Clear responsibilities of everyone involved in investigational drug dispersion
- Staff turnover issues



Standard operating procedure




"When In Doubt DON'T Throw It Out"

- Treat study drugs/documentation as controlled medications
 - Keep any files that you are unsure of their importance, expiration, or purpose
 - Consult UK IDS if needed
- Make sure to follow protocol-specific instructions regarding destruction and proceeding documentation
- Maintain drug accountability records for at minimum the time required by site- or protocol-specific recommendations.




Real-Time Documentation

- Stay up-to-date on recordkeeping by documenting in real-time
- Incomplete or incorrect documentation can lead to protocol deviations.



Common DARF Non-Compliance Issues




Examples of DARF Non-Compliance

Collection control ar Departme Public rej information	Print Form Save As Reset Form Collection of this information is authorized under 21 CFR 312.57. This information is collected to ensure compliance with Food and Drug Administration (FDA) requirements for NCI as an IND sponsor and that investigational agents are under the control and accounted for by competent authority. The information is outlutary, however, in order for you to conduct a study in accordance with relevant, current protocols, you must complete all fields. Public reporting burden for this collection of information is estimated to average 4 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information inductor sponsor, and a person is not required to respond to, a collection of information unders it displays a currently valid OMB control number. Send comments regarding this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 2092-7974, Bethesda, MD 2092-7) 0	orm Approve MB No. 0925 xpires: 03/3	-0613 1/2020		
	of Institution: /ersity of	Kentuck	y	Investigator Name: John Doe, MD				SATELLITE RECORD CTEP Investigator ID:					Cale	6 () 8 9 10 13 14 15 16 17		
Protoco Oral		ophen fo	r Post-Surgical	Pain		NCI Protocol No: Local Protocol No: XYZ-123			Dispensing Area: Investigational Drug Service Pharmac					18 19 25 2	13 14 15 13 14 20 21 22 23 30 34 6 21 28 29 30 34	
Agent Acet	Name: aminophe	n				Dose Form a	and Strength: 00mg				e.g., # tablets ets/bottle	/bottle):				
Line No.	Date	Patient's Initials	Patient's ID No.	Dose	Quantity Dispensed Receive	d or	nce Forward Balance	Manufacturer and Lot No.	Recorder's Initials	Expiration Date (if available)	Date Patient Returned	Quantity Patient Returned	Recorder's Initials		DARFs not f correctly or contain a	do not
1.	08/01/2020	DBL	12345678-90	500ma	1 bottl	le -	1/8	Johnson & Johnson 432-05	SL	11/20	8/30/20	D	SL		information	
2.	09/01/2020	DBL	12345678-90	500119	Thot+	-le -	-1/7	Johnson & Johnson 432-05	SL		9/30/20	3 tablets	SL		header that is	required
3.	10/01/2020	DBL	12345678-90	500mg	1 bot		16	Johnson & Johnson 432-05	SL	11/20	10/30/20	6 tablets	SL			
4.	11/01/2020	DBL	12345678-90	500mg	1 bott	- P - 1	15	Johnson & Johnson 488-05	SL	11/20	11/30/20	2 tablets	SL		One DARF ι	used for
5.	12/01/2020	DBL	12345678-90	1000mg	1 IV		1/4	Johnson & Johnson 488-05	SL	11/20					multiple a	
6. 7.															strengths, c forms, or or investigat	losage dering

Develop generic oral and IV drug accountability form templates for easier implementation of new/expired research medication dispositior

- easier implementation of new/expired research medication disposition documentation
 - Suggested format for name: "Study Name/Code Agent Strength DARF Expiration Date"



- **NCI Drug Accountability Record Template**
- Create a shared folder for drug accountability forms
 - Share access with other investigational pharmacists/technicians



DARF Assistance

	DADR Local Destruction Agent Returns Agent Transfers Datient-Specific DARFs Agent Dispensing Agent Receipt Oral DARF DARF Header DARF Basics	One Drug Form One Dose One DARE One Drug
Pharmaceutical Management Branch Investigational Drug Accountability:	DARF Basics	Dose DARF Drug
National Cancer Institute ctep.ca	ancer.gov	

- NIH/NCI Investigational Drug Accountability Training Videos
 - https://ctep.cancer.gov/branches/pmb/drug_training_videos.htm
- Maintaining in-date DARFs NCI/CTEP sends out automated reminders.

One

Protocol



Single Drug Accountability Record Forms (DARFs) can only be used for one drug, for one strength, for one dosage form, for one study.

TRUE

Other Non-Compliance Examples

- Quantities not accounted for in physical inventory; quantity does not match DARF
 - Treat everything as a control
 - Ramifications of inaccurate documentation protocol deviations/audits/CAPA

- Unused/un-dispensed NCI-supplied study agent is not returned or not transferred to an appropriate NCI protocol or not destroyed within 90 days of notification from NCI;
- NCI-supplied study agent is locally destroyed without NCI authorization or not locally destroyed per local institution's destruction policy





Other Non-Compliance Examples (cont.)

- Pharmacy does not have procedures in place to ensure person prescribing or cosigning prescriptions for study-supplied agent is an authorized prescriber
 - Verify active prescriber authorization via the CTSU website: https://www.ctsu.org/Public/Default.aspx



- Participant given commercial supply instead of the study supplied agent
 - Cannot replace research provided medications with commercial supply

TRUE OR FALSE

If a drug is commercially available and is used by mistake for a study specific dose, the pharmacy can restock their inventory with the study supplied drug.

QUESTIONS?

General IDS Email: IDS@uky.edu